An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women

International Journal of STD and AIDS

Volumn 17, Issue 7, 2006, Pages 448-452

  Garland, S M ^a,b   Waddell, R ^c   Mindel, A ^d,g   Denham, M ^e   McCloskey, J C ^f  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Clinic 275   (Australia)

^d SYDNEY EYE HOSPITAL   (Australia)

^e MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

^f ROYAL PERTH HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Duration of treatment; Genital warts; Imiquimod

Indexed keywords

IMIQUIMOD;

ADOLESCENT; ADULT; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DATA ANALYSIS; DISEASE DURATION; DRUG CLEARANCE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; INCIDENCE; LOCAL SKIN REACTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN EDEMA; SKIN ULCER; SWELLING; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AMINOQUINOLINES; CONDYLOMATA ACUMINATA; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; INTERFERON INDUCERS; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745880376     PISSN: 09564624     EISSN: 09564624     Source Type: Journal    
DOI: 10.1258/095646206777689161     Document Type: Article

References (12)

1. Koutsky LA. Epidemiology of genital papillomavirus infection. Am J Med 1997;102:3-8
2. Coleman N, Birley HDL, Renton AM, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994;102:768-74
3. Avgerinou G, Georgala S, Theodoridis A, et al. Reduction of cell mediated immunity in patients with genital warts of long duration. Genitourin Med 1986;62:396-8
4. Tyring SK, Arany I, Stanley MA, et al. A randomised controlled molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178:551-5
5. Miller RI, Gerster JF, Owens ML, et al. Imiquimod applied topically; a novel immune response modifier and a new class of drug. Int J Immunopharmacol 1999;21:1-14
6. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25-30
7. Beutner KR, Tyring SK, Trofatter KF, et al. Imiquimod, a patientappplied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998;42:789-94
8. Moore RA, Edwards JE, Hopwood J, et al. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis 2001;1:3
9. Garland SM, Sellors JW, Wikstrom A, et al. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts - results of an open-label, multicentre phase IIIB trial. Int J STD AIDS 2001;12:722-9
10. Lacey CJN, Goodall RL, Ragnarson Tennvall G, et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003;79:270-5
11. O'Mahony C, Law C, Gollnick HPM, et al. New patientapplied therapy for anogenital warts is rated favourably by patients. Int J STD AIDS 2001;12:565-70
12. Streeton C, Harris A. Treatment patterns of external genital warts in Australian general practice. Venereology 1998;11:20-5